Indo-Bangla Pharmaceuticals Limited (DSE: IBP)
Bangladesh
· Delayed Price · Currency is BDT 9.00
-0.10 (-1.10%)
At close: Nov 14, 2024
IBP Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jul '22 Jul 1, 2022 | Jul '21 Jul 1, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2015 |
| Revenue | 211.61 | 374.48 | 484.68 | 782.24 | 866.1 | 740.71 | Upgrade
|
| Revenue Growth (YoY) | -43.54% | -22.74% | -38.04% | -9.68% | 16.93% | 12.23% | Upgrade
|
| Cost of Revenue | 182.04 | 277.92 | 337.75 | 469.3 | 521.57 | 444.16 | Upgrade
|
| Gross Profit | 29.58 | 96.56 | 146.93 | 312.94 | 344.53 | 296.55 | Upgrade
|
| Selling, General & Admin | 31.94 | 67.88 | 111.13 | 139.64 | 132.71 | 127.31 | Upgrade
|
| Operating Expenses | 31.94 | 67.88 | 111.13 | 139.64 | 132.71 | 127.31 | Upgrade
|
| Operating Income | -2.36 | 28.68 | 35.8 | 173.3 | 211.82 | 169.24 | Upgrade
|
| Interest Expense | -4.11 | -5.23 | -4.88 | -3.81 | - | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | 2.16 | 10.89 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.45 | 0.42 | 0.8 | 0.63 | 3.03 | 4.83 | Upgrade
|
| EBT Excluding Unusual Items | -6.92 | 23.87 | 31.72 | 170.11 | 217.01 | 184.96 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.7 | 0.7 | - | -0.77 | - | -4.19 | Upgrade
|
| Pretax Income | -6.22 | 24.57 | 31.72 | 169.34 | 217.01 | 180.78 | Upgrade
|
| Income Tax Expense | 11.87 | 16.17 | 6.55 | 34.62 | 60.76 | 25.55 | Upgrade
|
| Net Income | -18.08 | 8.41 | 25.17 | 134.73 | 156.24 | 155.23 | Upgrade
|
| Net Income to Common | -18.08 | 8.41 | 25.17 | 134.73 | 156.24 | 155.23 | Upgrade
|
| Net Income Growth | - | -66.60% | -81.31% | -13.77% | 0.66% | 57.60% | Upgrade
|
| Shares Outstanding (Basic) | 111 | 116 | 116 | 114 | 114 | 100 | Upgrade
|
| Shares Outstanding (Diluted) | 111 | 116 | 116 | 114 | 114 | 100 | Upgrade
|
| Shares Change (YoY) | -5.98% | - | 2.17% | - | 13.37% | 9.64% | Upgrade
|
| EPS (Basic) | -0.16 | 0.07 | 0.22 | 1.18 | 1.37 | 1.55 | Upgrade
|
| EPS (Diluted) | -0.16 | 0.07 | 0.22 | 1.18 | 1.37 | 1.55 | Upgrade
|
| EPS Growth | - | -66.60% | -81.71% | -13.77% | -11.22% | 43.74% | Upgrade
|
| Free Cash Flow | 74.93 | 42.92 | 47.6 | -49.39 | -133.47 | -15.2 | Upgrade
|
| Free Cash Flow Per Share | 0.67 | 0.37 | 0.41 | -0.43 | -1.17 | -0.15 | Upgrade
|
| Dividend Per Share | - | - | 0.100 | 0.400 | - | 0.196 | Upgrade
|
| Dividend Growth | - | - | -75.00% | - | - | - | Upgrade
|
| Gross Margin | 13.98% | 25.79% | 30.31% | 40.01% | 39.78% | 40.04% | Upgrade
|
| Operating Margin | -1.12% | 7.66% | 7.39% | 22.15% | 24.46% | 22.85% | Upgrade
|
| Profit Margin | -8.55% | 2.24% | 5.19% | 17.22% | 18.04% | 20.96% | Upgrade
|
| Free Cash Flow Margin | 35.41% | 11.46% | 9.82% | -6.31% | -15.41% | -2.05% | Upgrade
|
| EBITDA | 35.42 | 67.05 | 74.93 | 209.2 | 240.72 | 191.22 | Upgrade
|
| EBITDA Margin | 16.74% | 17.90% | 15.46% | 26.74% | 27.79% | 25.82% | Upgrade
|
| D&A For EBITDA | 37.79 | 38.36 | 39.13 | 35.9 | 28.9 | 21.97 | Upgrade
|
| EBIT | -2.36 | 28.68 | 35.8 | 173.3 | 211.82 | 169.24 | Upgrade
|
| EBIT Margin | -1.12% | 7.66% | 7.39% | 22.15% | 24.46% | 22.85% | Upgrade
|
| Effective Tax Rate | - | 65.79% | 20.64% | 20.44% | 28.00% | 14.13% | Upgrade
|
| Advertising Expenses | - | 0.77 | 4.19 | 7.02 | 7.11 | 6.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.